Back to Search
Start Over
Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
- Source :
- American Journal of Hematology; Apr2024, Vol. 99 Issue 4, p774-779, 6p
- Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 03618609
- Volume :
- 99
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- American Journal of Hematology
- Publication Type :
- Academic Journal
- Accession number :
- 176104901
- Full Text :
- https://doi.org/10.1002/ajh.27245